학술논문

An updated database of human maximum skin fluxes and epidermal permeability coefficients for drugs, xenobiotics, and other solutes applied as aqueous solutions
Document Type
article
Source
Data in Brief, Vol 42, Iss , Pp 108242- (2022)
Subject
Percutaneous absorption
maximum flux
epidermal permeability
in vitro human skin penetration test (IVPT)
quantitative structure-property relationship (QSPR)
xenobiotics
Computer applications to medicine. Medical informatics
R858-859.7
Science (General)
Q1-390
Language
English
ISSN
2352-3409
Abstract
The dataset represented in this article is referred to by the review article entitled “Topical drug delivery: history, percutaneous absorption, and product development” (MS Roberts et al., 2021) [1]. The dataset contains maximal flux (Jmax), and permeability coefficient (kp) values collated from In Vitro human skin Permeation Test (IVPT) reports published to date for various drugs, xenobiotics, and other solutes applied to human epidermis from aqueous solutions. Also included are each solute's physicochemical properties and the experimental conditions, such as temperature, skin thickness, and skin integrity, under which the data was generated. This database is limited to diluted or saturated aqueous solutions of solutes applied on human epidermal membranes or isolated stratum corneum in large volumes so that there was minimal change in the donor phase concentration. Included in this paper are univariate Quantitative Structure-epidermal Permeability Relationships (QSPR) in which the solute epidermal permeation parameters (kp, and Jmax) are related to potential individual solute physicochemical properties, such as molecular weight (MW), log octanol-water partition coefficient (log P), melting point (MP), hydrogen bonding (acceptor - Ha, donor – Hd), by scatter plots. This data was used in the associated review article to externally validate existing QSPR regression equations used to forecast the kp and Jmax for new therapeutic agents and chemicals. The data may also be useful in developing new QSPRs that may aid in: (1) drug choice and (2) product design for both topical and transdermal delivery, as well as (3) characterizing the potential skin exposure of hazardous substances.